Biogen’s Immunology Buying Spree Reveals a Strategy the Neurology Playbook Can No Longer Support
Biogen's $1B RayThera deal is its second major immunology acquisition in two years. A pipeline pivot this deliberate signals...
immunology
argenx’s $1.3 Billion Quarter Proves FcRn Dominance — Now the Real Test Begins
argenx hit $1.3B in Q1 2026 product sales, up 63% YoY. With two VYVGART label expansions pending and empasiprubart...
AbbVie’s Post-Humira Safety Net Has a Hole in It — and J&J Just Found It
BNP Paribas flagged J&J's oral psoriasis candidate as a credible Skyrizi rival, and Wall Street mostly shrugged. They shouldn't...